Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) protects and informs Canadian consumers by reviewing the prices of patented medicines sold in Canada, and by reporting on pharmaceutical trends.

We are an independent quasi-judicial body that is part of the Health portfolio, and operate at arm’s-length from the Minister of Health.

Department name

Follow:

We are in the process of moving our services and information to Canada.ca.

Our current Patented Medicine Prices Review Board website will remain available until the move to Canada.ca is complete.

Latest news

Consultation Phase 2 : The Discussion Guide

Consultation Phase 2 : The Discussion Guide 

Comments to be received before September 11, 2024. Details on registration to the Webinar to learn more on the approach taken by the Board is coming soon. 

Meds Entry Watch 8th Edition

Meds Entry Watch 8th Edition

This edition of the report  explores the market entry of new medicines in Canada and other countries.

What we are doing

Corporate information

Management

Thomas J. Digby
Chairperson

Management

Guillaume Couillard
Director General

Features

Regulatory Process

The PMPRB is responsible for ensuring the prices that patentees charge for prescription and non-prescription patented medicines sold in Canada to wholesalers, hospitals, pharmacies or others, for human and veterinary use, are not excessive.

NPDUIS Analytical Studies

Every report and publication published by the NPDUIS group.

Consultations

Consultations

Effective and meaningful stakeholder involvement is essential to enable the PMPRB to fulfil its mandate, deliver programs, launch new initiatives, and build public trust.

Page details

Date modified: